Trevi Therapeutics, Inc.NASDAQ: TRVI

Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

· Issued by Trevi Therapeutics, Inc.

Haduvio met the primary endpoint with a statistically-significant reduction (p

Trevi Therapeutics, Inc. on 6ix

Story so far

Earlier from Trevi Therapeutics

Later from Trevi Therapeutics

All Trevi Therapeutics news releases